It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Staphylococcus aureus is a leading cause of nosocomial implant-associated infections, causing significant morbidity and mortality, underscoring the need for rapid, non-invasive, and cost-effective diagnostics. Here, we optimise the synthesis of renal-clearable gold nanoclusters (AuNCs) for enhanced catalytic activity with the aim of developing a sensitive colourimetric diagnostic for bacterial infection. All-atom molecular dynamics (MD) simulations confirm the stability of glutathione-coated AuNCs and surface access for peroxidase-like activity in complex physiological environments. We subsequently develop a biosensor by encapsulating these optimised AuNCs in bacterial toxin-responsive liposomes, which is extensively studied by various single-particle techniques. Upon exposure to S. aureus toxins, the liposomes rupture, releasing AuNCs that generate a colourimetric signal after kidney-mimetic filtration. The biosensor is further validated in vitro and in vivo using a hyaluronic acid (HA) hydrogel implant infection model. Urine samples collected from mice with bacteria-infected HA hydrogel implants turn blue upon substrate addition, confirming the suitability of the sensor for non-invasive detection of implant-associated infections. This platform has significant potential as a versatile, cost-effective diagnostic tool.
Implant-associated infections with Staphylococcus aureus pose serious clinical challenges. Here, the authors develop a biosensor based on toxin-responsive liposomes encapsulating gold nanoclusters, providing a non-invasive, colourimetric diagnostic tool for bacterial infection detection with urinary readout.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Imperial College London, Department of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
2 Imperial College London, Department of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); King’s College London, School of Cancer & Pharmaceutical Sciences, Institute of Pharmaceutical Science, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
3 RMIT University, School of Engineering, Melbourne, Australia (GRID:grid.1017.7) (ISNI:0000 0001 2163 3550)
4 Imperial College London, Department of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, Centre for Bacterial Resistance Biology (CBRB), Department of Infectious Disease, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, Department of Infectious Disease, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
5 Mattenstrasse 26, BioEM lab, Biozentrum, University of Basel, Basel, Switzerland (GRID:grid.6612.3) (ISNI:0000 0004 1937 0642)
6 Imperial College London, Department of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, Department of Infectious Disease, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); University of Oxford, Department of Physiology, Anatomy and Genetics, Department of Engineering Science, Kavli Institute for Nanoscience Discovery, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
7 University of Oxford, Department of Physiology, Anatomy and Genetics, Department of Engineering Science, Kavli Institute for Nanoscience Discovery, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
8 Imperial College London, Department of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Karolinska Institutet, Department of Medical Biochemistry and Biophysics, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
9 University College London, Department of Chemistry, London, UK (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201)
10 Imperial College London, Department of Infectious Disease, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
11 Imperial College London, Centre for Bacterial Resistance Biology (CBRB), Department of Infectious Disease, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, Department of Infectious Disease, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
12 Imperial College London, Department of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); University of Oxford, Department of Physiology, Anatomy and Genetics, Department of Engineering Science, Kavli Institute for Nanoscience Discovery, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Karolinska Institutet, Department of Medical Biochemistry and Biophysics, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)